PapersFlow Research Brief
Colorectal Cancer Treatments and Studies
Research Guide
What is Colorectal Cancer Treatments and Studies?
Colorectal Cancer Treatments and Studies encompass research advancements in therapies for colorectal cancer, including the use of cetuximab and bevacizumab, the influence of KRAS and BRAF mutations on treatment response, chemotherapy efficacy, and molecular subtypes enabling precision medicine.
This field includes 59,340 works focused on molecular mechanisms of metastatic colorectal cancer and EGFR inhibitors. Key studies demonstrate that adding bevacizumab to fluorouracil-based chemotherapy improves survival in metastatic colorectal cancer patients. Foundational genetic models identify sequential alterations driving colorectal tumorigenesis.
Topic Hierarchy
Research Sub-Topics
KRAS Mutations Colorectal Cancer
This sub-topic investigates the prognostic and predictive role of KRAS mutations in metastatic colorectal cancer. Researchers study resistance mechanisms to EGFR-targeted therapies and novel inhibitors.
Cetuximab Efficacy Metastatic CRC
This sub-topic evaluates cetuximab in combination regimens for RAS wild-type metastatic colorectal cancer. Researchers analyze biomarkers, response rates, and survival outcomes from clinical trials.
BRAF Mutations Colorectal Cancer
This sub-topic examines BRAF V600E prevalence, aggressive tumor biology, and targeted therapy responses. Researchers explore immunotherapy combinations for BRAF-mutant CRC.
Bevacizumab Colorectal Cancer Therapy
This sub-topic assesses anti-VEGF therapy with bevacizumab in first-line metastatic CRC treatment. Researchers investigate hypertension biomarkers and optimal sequencing with chemotherapy.
Molecular Subtypes Colorectal Cancer
This sub-topic develops consensus molecular classification (CMS) systems for CRC heterogeneity. Researchers correlate subtypes with therapeutic vulnerabilities and immune landscapes.
Why It Matters
Bevacizumab combined with irinotecan, fluorouracil, and leucovorin extended survival in metastatic colorectal cancer patients, as shown in a trial where the addition resulted in statistically significant improvements (Hurwitz et al., 2004, "Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer"). Genetic studies reveal ras-gene mutations and allelic deletions on chromosomes 5, 17, and 18 during colorectal tumor development, informing targeted screening and intervention (Vogelstein et al., 1988, "Genetic Alterations during Colorectal-Tumor Development"). These findings support precision medicine by linking mutations like KRAS and BRAF to therapy outcomes in oncology practice.
Reading Guide
Where to Start
"A genetic model for colorectal tumorigenesis" by Fearon and Vogelstein (1990), as it provides the foundational sequence of genetic events in colorectal cancer development, essential for understanding subsequent treatment studies.
Key Papers Explained
Fearon and Vogelstein (1990, "A genetic model for colorectal tumorigenesis") establishes the multistep genetic pathway, built upon by Vogelstein et al. (1988, "Genetic Alterations during Colorectal-Tumor Development"), which details specific ras mutations and chromosomal deletions across tumor stages. Hurwitz et al. (2004, "Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer") applies these insights to treatment, showing bevacizumab enhances chemotherapy survival in metastatic cases linked to such genetics.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research centers on KRAS/BRAF mutations' role in EGFR inhibitor resistance and molecular subtypes for precision medicine, as emphasized in the 59,340 works cluster. No recent preprints or news alter these focuses.
Papers at a Glance
Frequently Asked Questions
What genetic alterations occur during colorectal tumor development?
ras-gene mutations and allelic deletions of chromosomes 5, 17, and 18 are observed in colorectal adenomas and carcinomas. Vogelstein et al. (1988) analyzed different stages of neoplasia and found these changes accumulate progressively. Such alterations help explain tumor progression from benign to malignant states.
How does bevacizumab improve outcomes in metastatic colorectal cancer?
Bevacizumab added to fluorouracil-based combination chemotherapy yields statistically significant survival improvements. Hurwitz et al. (2004) reported clinically meaningful benefits in a trial for metastatic patients. This combination targets vascular endothelial growth factor to inhibit tumor angiogenesis.
What role do KRAS and BRAF mutations play in colorectal cancer treatment?
KRAS and BRAF mutations affect responsiveness to EGFR inhibitors like cetuximab in metastatic colorectal cancer. Studies in this cluster highlight their impact on precision medicine approaches. These mutations predict poor outcomes with certain targeted therapies.
What is the genetic model for colorectal tumorigenesis?
Fearon and Vogelstein (1990) proposed a model outlining sequential genetic events leading to colorectal cancer. It integrates data from multiple tumor stages and genetic analyses. This framework guides research into molecular subtypes.
How do molecular subtypes contribute to precision medicine in colorectal cancer?
Molecular subtypes based on mutations enable tailored treatments like chemotherapy or EGFR inhibitors. Research emphasizes KRAS, BRAF, and EGFR pathways for patient stratification. This approach improves efficacy by matching therapies to tumor genetics.
Open Research Questions
- ? How can KRAS and BRAF mutations be overcome to restore EGFR inhibitor efficacy in metastatic colorectal cancer?
- ? What sequential genetic events beyond known chromosomal deletions drive progression in molecular subtypes of colorectal tumors?
- ? Which combination chemotherapies optimize survival in bevacizumab-resistant colorectal cancer patients?
- ? How do molecular mechanisms of cetuximab resistance inform next-generation precision medicine strategies?
Recent Trends
The field maintains 59,340 works with emphasis on cetuximab, bevacizumab, KRAS/BRAF mutations, and chemotherapy in metastatic colorectal cancer.
No growth rate data or recent preprints/news indicate shifts.
Seminal papers like Hurwitz et al. continue dominating citations.
2004Research Colorectal Cancer Treatments and Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Colorectal Cancer Treatments and Studies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers